03/01
Headlines

NASDAQ:BCRX

Healthcare Bearish Stocks: AcelRx Pharmaceuticals (NASDAQ:ACRX), BioCryst Pharmaceuticals (NASDAQ:BCRX), Baxano Surgical (NASDAQ:BAXS), Flamel Technologies (NASDAQ:FLML)

Mark DeFrance02 mins

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will present a Company update. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) stock performance was -8.38% in last session and finished the day at $11.92….

Read More

Biotech Gainers In News: Inovio Pharmaceuticals (NYSEMKT:INO), Dendreon Corporation (NASDAQ:DNDN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax (NASDAQ:DYAX)

Colin Pettis02 mins

Inovio Pharmaceuticals Inc (NYSEMKT:INO) on Feb. 27 announced the pricing of an underwritten public offering of 18,966,000 shares of common stock for a public offering price of $2.90 per share. The gross proceeds to Inovio from this offering are expected to be approximately $55 million, before deducting the underwriting discounts and commissions and other estimated…

Read More

Investors Should Watch: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), American Airlines Group Inc. (NASDAQ:AAL), General Communication Inc. (NASDAQ:GNCMA), BioCryst Pharmaceuticals (NASDAQ:BCRX), OceanFirst Financial (NASDAQ:OCFC)

Chris Lewis03 mins

On Jan 22, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that Birgit M. Schoeberl, Ph.D. has been named the new head of its Discovery division. Ulrik B. Nielsen, Ph.D. will be stepping down as the head of the Discovery division and has been elected to serve on Merrimack’s Board of Directors. Anthony J. Sinskey, Sc.D. will also…

Read More

Moving Stocks: Cubist Pharmaceuticals Inc. (NASDAQ:CBST), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Riverbed Technology, Inc. (NASDAQ:RVBD), eHealth, Inc. (NASDAQ:EHTH), IDEX Corporation (NYSE:IEX)

John Meady02 mins

Merck (MRK) announced it’s buying the Cubist Pharmaceuticals Inc. (NASDAQ:CBST) for $102 per share. Cubist Pharmaceuticals Inc. does advanced antibiotic research and is noted for its research on superbugs — diseases that have developed immunity to antibiotic treatment. Cubist Pharmaceuticals Inc. (NASDAQ:CBST) belongs to Healthcare sector. Its net profit margin is 5.60% and weekly performance…

Read More

Big Movers : BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Eastman Chemical Co. (NYSE:EMN), Pike Corporation (NYSE:PIKE), General Motors Company (NYSE:GM)

Colin Pettis02 mins

BioCryst Pharmaceuticals (NASDAQ:BCRX) CFO Thomas R. Staab II unloaded 10,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $13.58, for a total transaction of $135,800.00. Following the completion of the transaction, the chief financial officer now directly owns 162,942 shares…

Read More
Gilead Sciences GILD NASDAQ:GILD

Biotech GAiners: BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax Corp. (NASDAQ:DYAX), Novavax, Inc. (NASDAQ:NVAX), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Kevin Long02 mins

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares closed up nearly 11% on Tuesday after the company reported positive data from its OPuS-1 mid-stage study involving BCX4161 as a treatment for hereditary angioedema, or HAE. This is a rare immune disorder that can cause swelling of the face, breathing airways, and also causes abdominal cramping. According to the…

Read More